Lunai Bioworks Inc(LNAI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.87 | Insider Own | 17.36% | Shs Outstand | 4.6M | Perf Week | -44.06% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 4.2M | Perf Month | -88.06% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 3.9% | Short Float | 2.8% | Perf Quarter | -93.1% |
| Income | -0.00B | P/S | 16.6 | EPS this Y | - | Inst Trans | 14.78% | Short Ratio | 0.3 | Perf Half Y | -93.56% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -39.21% | Short Interest | 0.12M | Perf YTD | -97.66% |
| Book/sh | -1.96 | P/C | 0.49 | EPS past 3/5Y | 73.42% 52.82% | ROE | -325.46% | 52W High | -98.76% ($13.28) | Perf Year | -97.85% |
| Cash/sh | 0.34 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 16.88% ($0.14) | Perf 3Y | -99.92% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 98.99% | Gross Margin | -79.88% | Volatility(W/M) | 33.59% 24.1% | Perf 5Y | -99.98% |
| Dividend TTM | - | EV/Sales | 9.2 | Sales Y/Y TTM | - | Oper. Margin | -15129.29% | ATR (14) | 0.16 | Perf 10Y | -99.86% |
| Dividend Ex-Date | - | Quick Ratio | 0.11 | EPS Q/Q | 99.28% | Profit Margin | -6851.97% | RSI (14) | 13.39 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.11 | Sales Q/Q | - | SMA20 | -77.65% ($0.72) | Beta | 0.17 | Target Price | - |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -89.74% ($1.56) | Rel Volume | 0 | Prev Close | $0.16 |
| Employees | 12 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -94.34% ($2.83) | Avg Volume(3M) | 0.39M | Price | $0.16 |
| IPO | 2015/2/2 | Option/Short | No/Yes | Trades | 0 | Volume | - | Change | - |
🤖 Lunai BioWorks () is an AI biotech that combines AI, phenomics, and biological models to accelerate new drug target discovery and the development of chemical defense and central nervous system (CNS) therapeutics. The company is advancing multiple programs targeting CNS diseases such as Alzheimer's, alcohol use disorder, and chemical/biological defense responses, and also operates a U.S. defense-related consortium through its subsidiary BioSymetrics.
Over the past 1 year, on the lower side
99% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
LNAI has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,660. Peers typically go for $917.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +57% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 3.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #595 of 598 in the industry
Based on market cap of $1M.
ARTL#591 Artelo Biosciences Inc $1M PER - 
JAGX#592 Jaguar Health Inc $1M PER - 
LABT#593 Lakewood-Amedex Biotherapeutics Inc $1M PER - 
SPRC#594 SciSparc Ltd $1M PER - LNAI#595 Lunai Bioworks Inc $1M PER - 
FAQ
What kind of company is LNAI?
LNAI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of LNAI?
The market cap of LNAI is approximately $1M, ranking 5,883 within its sector.
What is the 52-week high and low for LNAI?
LNAI has recorded a 52-week high of $13.28 and a low of $0.14.
